---
title: Reduce under and over stimulation
nct_id: NCT07682311
phase: NA
status: RECRUITING
sponsor: University of California, San Francisco
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07682311"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07682311"
last_fetched: "2026-07-02T14:00:31.704Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce under and over stimulation

**Goal (in five words):** Reduce under and over stimulation

**Official Title:** Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator

**Trial ID:** [NCT07682311](https://clinicaltrials.gov/study/NCT07682311)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University of California, San Francisco
- **Target Enrollment:** 40 participants
- **Start Date:** 2026-06
- **Completion Date:** 2030-05
- **Conditions:** PD - Parkinson's Disease
- **Interventions:** Medtronic Percept Deep Brain Stimulation (adaptive DBS), Medtronic Percept Deep Brain Stimulation (cDBS)
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to cut down times when people with Parkinson’s are under- or over-stimulated by standard therapy and to smooth out remaining problems like slowed movement, involuntary movements, or muscle tightness that persist despite deep brain stimulation. The approach tests an automated, data-driven system that recommends control settings for adaptive deep brain stimulation using the Medtronic Percept neurostimulator; the adaptive system reads brain signals in real time and automatically raises or lowers stimulation within preset limits to match changing needs during the day. Eligible participants are adults 25 to 75 with idiopathic Parkinson’s who already have a Percept device implanted for at least two months, have been on constant deep brain stimulation but still have significant motor fluctuations, and have no significant thinking problems (a score of 24 or higher on the Montreal Cognitive Assessment) and can attend follow-up visits.

## What This Actually Involves

**Placebo** _(From the protocol)_: This is a crossover trial: instead of staying in one group, you move through a sequence of assignments, so you receive the active treatment during at least one period of the study. Ask the coordinator for the exact sequence and how long each phase lasts.

**Visits** _(Ask the coordinator)_: Ask the coordinator how many in-person visits the study involves, how long each one takes, and over what total period.

**Procedures** _(From the protocol)_:
- Brain surgery / implanted device (Invasive)
  > "Medtronic Percept Deep Brain Stimulation (adaptive DBS)"
- Wearable / at-home monitoring (Non-invasive)
  > "In a first randomized, blinded study design comparing personalized aDBS to clinically optimized cDBS, aDBS significantly reduced the patient's most bothersome residual motor fluctuations, assessed both in blinded daily self-assessments, and objectively by wearable monitors, and…"

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 25 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Age 25-75.
2. Diagnosis of idiopathic PD.
3. Patient has undergone surgical intervention with deep brain stimulation (Percept device) for their disorder at least 2 months prior to recruitment.
4. Absence of significant cognitive impairment (score of 24 or greater on the Montreal Cognitive Assessment (MoCA)).
5. Signed informed consent.
6. Ability to comply with study follow-up visits for brain recording, testing of adaptive stimulation, and clinical assessment.
7. Patient has been on cDBS for at least two months and still experiences significant residual motor fluctuation while on cDBS. Consequently, patient is undergoing aDBS treatment currently or was recommended aDBS as part of clinical care to manage their residual motor fluctuation.
8. Has available cDBS Timeline LFP and stimulation data lasting at least 1 day.
9. To be enrolled in the clinical trial phase of the study, patient will need to consent to reverting back to their baseline cDBS settings for all required cDBS testings.

Exclusion Criteria:

1. Patient meets criteria for a psychogenic movement disorder.
2. Significant untreated depression (BDI-II score \>20). History of suicidal attempt or active suicidal ideation (Yes to #2-5 on C-SSRS).
3. Any personality or mood symptoms that study personnel believe will interfere with study requirements.
```

## Locations (1)

- University of California San Francisco, San Francisco, California, United States _(37.7749, -122.4194)_
  - Sarah Wang, PhD, (CONTACT), 415-353-7885, sarah.wang@ucsf.edu

## Central Contacts

- Research Coordinator, (CONTACT), 5175152739, sebastian.liu@ucsf.edu
- Research Manager, (CONTACT), sarah.wang@ucsf.edu

---

*Canonical: https://parkinsonspathways.com/trial/NCT07682311*  
*HTML version: https://parkinsonspathways.com/trial/NCT07682311*  
*Source data: https://clinicaltrials.gov/study/NCT07682311*